FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Mol Ther Nucleic Acids / Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver ...
Molecular therapy. Nucleic acids2013; 2(2); e70; doi: 10.1038/mtna.2012.61

Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis.

Abstract: Osteoarthritis (OA) affects over 40 million people annually. We evaluated interleukin-1 receptor antagonist (IL-1ra) gene transfer in an equine model based on IL-1ra protein therapy which inhibits inflammation through blocking IL-1. Using the self-complementary adeno-associated virus (scAAV)IL-1ra equine gene as a starting construct, we optimized the transgene cassette by analyzing promoters (cytomegalovirus (CMV) versus chicken β-actin hybrid (CBh)), coding sequences (optimized versus unoptimized), vector capsid (serotype 2 versus chimeric capsid), and biological activity in vitro. AAV serotypes 2 and 2.5 CMV scAAVoptIL-1ra were tested in equine joints. We evaluated two doses of scAAVIL-1ra, scAAVGFP, and saline. We developed a novel endoscopy procedure and confirmed vector-derived transgene expression (GFP) in chondrocytes 6 months post-injection. AAVIL-1ra therapeutic protein levels were 200-800 ng/ml of synovial fluid over 23 and 186 days, respectively. No evidence of intra-articular toxicity was detected and no vector genomes were found in contralateral joints based on GFP fluorescence microscopy and quantitative PCR. Finally, we assayed vector-derived IL-1ra activity based on functional assays which supported anti-inflammatory activity of our protein. These studies represent the first large animal intra-articular gene transfer approach with a therapeutic gene using scAAV and demonstrate high levels of protein production over extended time supporting further clinical investigation using scAAV gene therapy for OA.Molecular Therapy - Nucleic Acids (2013) 2, e70; doi:10.1038/mtna.2012.61; published online 5 February 2013.
Get Full Text
Publication Date: 2013-02-05 PubMed ID: 23385523PubMed Central: PMC3586798DOI: 10.1038/mtna.2012.61Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article discusses an experiment done to optimize a model using a gene linked to treatment strategies for Osteoarthritis (OA). Based on interleukin-1 receptor antagonist (IL-1ra) protein therapy, the researchers used an equine model for gene transfer and tested different factors for effective delivery of high levels of therapeutic protein. The results showed no toxicity within joint areas and high protein production over an extended period.

Objective of the Research

  • The primary goal of this research was to optimize a gene transfer model based on a specific protein therapy (IL-1ra) for alleviating inflammation related to Osteoarthritis (OA). The optimization process involved evaluating and testing various elements such as the promoters, coding sequences, vector capsid, and biological activity of the gene.

Methodology

  • The transgene cassette was optimized by comparing promoters (cytomegalovirus (CMV) versus chicken β-actin hybrid (CBh)), coding sequences (optimized versus unoptimized), and vector capsid (serotype 2 versus chimeric capsid).
  • The researchers subsequently conducted biological activity tests of the gene in vitro.
  • The researchers introduced the selected gene with optimized elements into equine joints and assessed the outcome for two different doses compared against a control group.
  • Finally, a novel endoscopy procedure was developed to confirm the expression of the injected gene in chondrocytes, the cells that make up cartilage, over six months post-injection.

Results and Findings

  • The protein molecules produced from the gene transfer were found in high levels (200-800 ng/ml) in synovial fluid, the lubricating liquid in joints, over an extended time (between 23 and 186 days post-injection).
  • No evidence of toxicity within the joint areas was detected, a vital factor considering the critical function of joints and the potential adverse effects that could arise from it.
  • In addition, no vector genomes were found in contralateral joints, suggesting that the gene transfer was localized and did not spread unnecessarily to other joint areas.
  • The presence of IL-1ra activity was confirmed through functional assays, proving that the therapeutic protein produced did possess anti-inflammatory activity.

Significance and Conclusions

  • This research represents one of the first advances in large-animal intra-articular gene transfer approaches using a therapeutic gene.
  • The study’s findings are promising and demonstrate high levels of protein production over extended periods, making it a possible solution for therapy in treating OA.
  • However, further investigation and clinical studies using this gene therapy technique for Osteoarthritis are required to validate and strengthen the research findings.

Cite This Article

APA
Goodrich LR, Phillips JN, McIlwraith CW, Foti SB, Grieger JC, Gray SJ, Samulski RJ. (2013). Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol Ther Nucleic Acids, 2(2), e70. https://doi.org/10.1038/mtna.2012.61

Publication

Molecular therapy. Nucleic acids
ISSN: 2162-2531
NlmUniqueID: 101581621
Country: United States
Language: English
Volume: 2
Issue: 2
Pages: e70

Researcher Affiliations

Goodrich, Laurie R
  • Orthopaedic Research Center, College of Veterinary Medicine, Colorado State University, Fort Collins, Colorado, USA.
Phillips, Jennifer N
    McIlwraith, C Wayne
      Foti, Stacey B
        Grieger, Joshua C
          Gray, Steven J
            Samulski, R Jude

              Grant Funding

              • K08 AR054903 / NIAMS NIH HHS
              • R01 AI072176 / NIAID NIH HHS
              • U54 AR056953 / NIAMS NIH HHS

              References

              This article includes 55 references
              1. Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis.. J Rheumatol 2008;35:2306–2312.
                pubmed: 18925684
              2. Buckwalter JA, Brown TD. Joint injury, repair, and remodeling: roles in post-traumatic osteoarthritis.. Clin Orthop Relat Res 2004. pp. 7–16.
                pubmed: 15232420
              3. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.. Immunol Today 1991;12:404–410.
                pubmed: 1838480
              4. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.. J Fam Pract 2002;51:530–537.
                pubmed: 12100776
              5. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41 1591–1602.
                pubmed: 9751091
              6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.. JAMA 2006;296:1633–1644.
                pubmed: 16968831
              7. Barnhill JG, Fye CL, Williams DW, Reda DJ, Harris CL, Clegg DO. Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial.. J Am Pharm Assoc (2003) 2006;46:14–24.
                pubmed: 16529337
              8. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354 795–808.
                pubmed: 16495392
              9. Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 52 779–786.
                pubmed: 15751094
              10. Uebelhart D, Malaise M, Marcolongo R, de Vathaire F, DeVathaire F, Piperno M. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil 12 269–276.
                pubmed: 15023378
              11. Frisbie DD, Kawcak CE, McIlwraith CW, Werpy NM. Evaluation of polysulfated glycosaminoglycan or sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced osteoarthritis.. Am J Vet Res 2009;70:203–209.
                pubmed: 19231952
              12. Arend WP. Interleukin-1 receptor antagonist.. Adv Immunol 1993;54:167–227.
                pubmed: 8379462
              13. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.. J Clin Invest 1990;85:1694–1697.
                pmc: PMC296623pubmed: 2139669
              14. Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 149 1054–1062.
                pubmed: 1386092
              15. Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthr Cartil 16 498–505.
                pubmed: 17825587
              16. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.. Am J Vet Res 2007;68:290–296.
                pubmed: 17331019
              17. Goodrich LR, Brower-Toland BD, Warnick L, Robbins PD, Evans CH, Nixon AJ. Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations.. Gene Ther 2006;13:1253–1262.
                pubmed: 16708081
              18. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene.. Gene Ther 2002;9:12–20.
                pubmed: 11850718
              19. Kay JD, Gouze E, Oligino TJ, Gouze JN, Watson RS, Levings PP. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med 11 605–614.
                pmc: PMC2876984pubmed: 19384892
              20. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102 8698–8703.
                pmc: PMC1150836pubmed: 15939878
              21. Payne KA, Lee HH, Haleem AM, Martins C, Yuan Z, Qiao C. Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees. Osteoarthr Cartil 19 1058–1065.
                pmc: PMC3139006pubmed: 21571082
              22. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 90 10764–10768.
                pmc: PMC47858pubmed: 8248169
              23. Gouze E, Pawliuk R, Pilapil C, Gouze JN, Fleet C, Palmer GD. In vivo gene delivery to synovium by lentiviral vectors. Mol Ther 5 397–404.
                pubmed: 11945066
              24. Nixon AJ, Goodrich LR, Scimeca MS, Witte TH, Schnabel LV, Watts AE. Gene therapy in musculoskeletal repair. Ann N Y Acad Sci 1117 310–327.
                pubmed: 18056051
              25. Pan RY, Chen SL, Xiao X, Liu DW, Peng HJ, Tsao YP. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist.. Arthritis Rheum 2000;43:289–297.
                pubmed: 10693868
              26. Ishihara A, Bartlett JS, Bertone AL. Inflammation and immune response of intra-articular serotype 2 adeno-associated virus or adenovirus vectors in a large animal model.. Arthritis 2012;2012:735472.
                pmc: PMC3263587pubmed: 22288012
              27. Goodrich LR, Choi VW, Carbone BA, McIlwraith CW, Samulski RJ. Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors.. Hum Gene Ther 2009;20:1697–1702.
                pmc: PMC2861962pubmed: 19642864
              28. Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.. Blood 2008;112:4532–4541.
                pmc: PMC2954682pubmed: 18716130
              29. Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. AAV's anatomy: roadmap for optimizing vectors for translational success.. Curr Gene Ther 2010;10:319–340.
                pmc: PMC3920455pubmed: 20712583
              30. Ortolano S, Spuch C, Navarro C. Present and future of adeno associated virus based gene therapy approaches.. Recent Pat Endocr Metab Immune Drug Discov 2012;6:47–66.
                pubmed: 22264214
              31. Byers S, Rothe M, Lalic J, Koldej R, Anson DS. Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues.. Mol Genet Metab 2009;97:102–108.
                pubmed: 19307142
              32. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.. Am J Vet Res 2007;68:290–296.
                pubmed: 17331019
              33. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 2357–2365.
                pmc: PMC3265081pubmed: 22149959
              34. Gouze E, Gouze JN, Palmer GD, Pilapil C, Evans CH, Ghivizzani SC. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases.. Mol Ther 2007;15:1114–1120.
                pubmed: 17440444
              35. Frisbie DD, McIlwraith CW. Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis.. Clin Orthop Relat Res 2000. pp. S273–S287.
                pubmed: 11039781
              36. Izal I, Acosta CA, Ripalda P, Zaratiegui M, Ruiz J, Forriol F. IGF-1 gene therapy to protect articular cartilage in a rat model of joint damage.. Arch Orthop Trauma Surg 2008;128:239–247.
                pubmed: 17661064
              37. Boissier MC, Lemeiter D, Clavel C, Valvason C, Laroche L, Begue T. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Hum Gene Ther 18 525–535.
                pubmed: 17532727
              38. Hu C, Lipshutz GS. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice.. Gene Ther 2012;19:1166–1176.
                pmc: PMC3432168pubmed: 22241178
              39. Bell P, Wang L, Gao G, Haskins ME, Tarantal AF, McCarter RJ. Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Mol Genet Metab 104 395–403.
                pmc: PMC3269907pubmed: 21778099
              40. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22 1143–1153.
                pmc: PMC3177952pubmed: 21476867
              41. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase ½ Study. J Rheumatol 37 692–703.
                pubmed: 20032102
              42. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 95 4613–4618.
                pmc: PMC22538pubmed: 9539786
              43. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 162 3625–3632.
                pubmed: 10092823
              44. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95 13859–13864.
                pmc: PMC24931pubmed: 9811891
              45. Kim SH, Lechman ER, Kim S, Nash J, Oligino TJ, Robbins PD. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis.. Mol Ther 2002;6:591–600.
                pubmed: 12409257
              46. Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 163 2202–2208.
                pubmed: 10438962
              47. Ishihara AB, Bertone AL. Biologic response to intra-articular Ad/AAV BMP2 vectors. 56th Annual Meeing of the Orthopaedic Research Society, New Orleans 2010.
              48. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.. Gene Ther 2001;8:1248–1254.
                pubmed: 11509958
              49. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.. J Virol 1998;72:2224–2232.
                pmc: PMC109519pubmed: 9499080
              50. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76 791–801.
                pmc: PMC136844pubmed: 11752169
              51. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20 443–455.
                pmc: PMC3277234pubmed: 22068425
              52. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo.. Gene Ther 2003;10:2112–2118.
                pubmed: 14625565
              53. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors.. Nat Protoc 2006;1:1412–1428.
                pubmed: 17406430
              54. Nixon AJ, Lust G, Vernier-Singer M. Isolation, propagation, and cryopreservation of equine articular chondrocytes.. Am J Vet Res 1992;53:2364–2370.
                pubmed: 1476323
              55. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.. Mol Ther 2011;19:1058–1069.
                pmc: PMC3129805pubmed: 21487395
              Subscribe to our newsletter
              Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.